Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid LeukemiaRoberta S. Azevedo, Nicholas J. Short, Tapan M. Kadia et al.|Blood|2025Cited by 2